Altimmune (NASDAQ:ALT) Receives "Buy" Rating from HC Wainwright

Altimmune (NASDAQ:ALT - Get Free Report)'s stock had its "buy" rating restated by stock analysts at HC Wainwright in a research report issued to clients and investors on Friday,Benzinga reports. They presently have a $12.00 price objective on the stock. HC Wainwright's price objective would indicate a potential upside of 232.41% from the company's current price.

Several other equities research analysts have also recently issued reports on ALT. William Blair reiterated a "market perform" rating on shares of Altimmune in a report on Friday, March 14th. Wall Street Zen lowered Altimmune from a "hold" rating to a "sell" rating in a research note on Saturday, June 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating, four have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Altimmune presently has an average rating of "Moderate Buy" and a consensus target price of $19.00.

Altimmune Stock Performance

ALT stock opened at $3.61 on Friday. Altimmune has a one year low of $2.90 and a one year high of $11.16. The firm's fifty day moving average is $5.77 and its 200 day moving average is $6.15. The firm has a market cap of $292.81 million, a PE ratio of -2.87 and a beta of 0.58.

Altimmune (NASDAQ:ALT - Get Free Report) last posted its earnings results on Tuesday, May 13th. The company reported ($0.26) EPS for the quarter, beating analysts' consensus estimates of ($0.35) by $0.09. The firm had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0.00 million. Altimmune had a negative return on equity of 65.44% and a negative net margin of 451,200.00%. During the same period last year, the firm earned ($0.34) EPS. Research analysts predict that Altimmune will post -1.35 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Altimmune

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Geneos Wealth Management Inc. acquired a new position in Altimmune in the 1st quarter valued at about $50,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Altimmune by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 48,901 shares of the company's stock valued at $247,000 after buying an additional 2,241 shares during the period. MetLife Investment Management LLC lifted its holdings in Altimmune by 5.4% in the first quarter. MetLife Investment Management LLC now owns 46,870 shares of the company's stock valued at $234,000 after acquiring an additional 2,396 shares during the last quarter. AlphaQuest LLC purchased a new position in Altimmune in the first quarter worth approximately $99,000. Finally, Hsbc Holdings PLC acquired a new stake in Altimmune during the first quarter worth $349,000. Institutional investors and hedge funds own 78.05% of the company's stock.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.